跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
(+)-2-(4-biphenyl)propionic acid
首页
药物
(+)-2-(4-biphenyl)propionic acid
Experimental
Small Molecule
(+)-2-(4-biphenyl)propionic acid
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
技术标识符
化学式
C
15
H
14
O
2
CAS 编号
10532-14-6
UNII ID
E4ZV1V9C3W
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ARB-NEPi complex, crystal forms, preparation methods and application
CN 110713465 A
申请人: SHANGHAI BOCIMED PHARMACEUTICAL CO LTD
优先权: 2017
CN
3 件公开
Heterocyclic compounds useful in the treatment of disease
US 10000459 B2
申请人: EPIGEN BIOSCIENCES INC
优先权: 2014
US
2 件公开
SOLID COMPOSITIONS COMPRISING AN OXADIAZOANTHRACENE COMPOUND AND METHODS OF MAKING AND USING THE SAME
US 2011064806 A1
申请人: TRANSTECH PHARMA INC
优先权: 2010
US
Flurbiprofen eugenol ester medical compound and preparation and preparation method thereof
CN 102964250 A
申请人: UNIV JILIN
优先权: 2012
CN
LCZ-696 novel crystal form and preparation method thereof
CN 106032361 A
申请人: QILU PHARMACEUTICAL CO LTD
优先权: 2015
CN
Diabetes mellitus resistant oral medicine composition
CN 105193796 A
申请人: ZHU ZHONGLIANG
优先权: 2015
CN
Antidiabetic oral drug composition
CN 105434433 A
申请人: ZHU ZHONGLIANG
优先权: 2015
CN
CN 105434434 A
申请人: ZHU ZHONGLIANG
优先权: 2015
CN
CN 105213380 A
申请人: ZHU ZHONGLIANG
优先权: 2015
CN
Anti-diabetic oral drug composition
CN 105232543 A
申请人: ZHU ZHONGLIANG
优先权: 2015
CN
CN 105232544 A
申请人: ZHU ZHONGLIANG
优先权: 2015
CN
CN 105232547 A
申请人: ZHU ZHONGLIANG
优先权: 2015
CN
Anti-diabetes oral pharmaceutical composition
CN 105287534 A
申请人: ZHU ZHONGLIANG
优先权: 2015
CN
CN 105213384 A
申请人: ZHU ZHONGLIANG
优先权: 2015
CN
CN 105287535 A
申请人: ZHU ZHONGLIANG
优先权: 2015
CN
New crystal form of anti-heart failure eutectic compound
CN 108299323 A
申请人: SHANGHAI DESANO PHARMACEUTICAL CO LTD
优先权: 2017
CN
第 1 / 2 页
上一页
下一页
药物
反馈